Bausch + Lomb Q2 Earnings Call Highlights
Adjusted gross margin was 62.2%, up 160 basis points year over year, supported by a higher mix of premium products in pharmaceuticals and surgical, as well as productivity efforts. The company invested $114 million in adjusted research and development, an increase of 19% from the prior-year period. Adjusted SG&A margin improved by approximately 130 basis points. Bausch + Lomb raised its 2026 revenue guidance by $20 million to a range of $5.440 billion to $5.540 billion.
How this was made
The 30-second read
Why it matters
The most tradable elements are the raised full-year revenue and adjusted EBITDA guidance ranges, plus quantified margin improvements and specific clinical/regulatory timelines that can drive estimate revisions and event-driven positioning.
Market read
Guidance uplift and quantified margin/EBITDA targets are likely to move BLCO estimates and sentiment, while upcoming clinical and FDA milestones set a near-to-medium term catalyst calendar.
What to watch
The guidance includes currency-benefit assumptions and a leverage target (net leverage 3.5x by end-2028); changes in FX or deleveraging pace could offset the headline upside.
Background
The piece summarizes Bausch + Lomb’s Q2 earnings call highlights, including margin performance, updated 2026 guidance, and pipeline/regulatory timing for dry-eye and glaucoma products.
Ticker impact
Bausch + Lomb raised 2026 revenue guidance by $20 million to $5.440B-$5.540B and lifted adjusted EBITDA guidance to $1.025B-$1.075B.
Moderately positive bias for BLCO over the next days to weeks, with follow-through contingent on dry-eye and surgical regulatory milestones.
The article provides specific, time-relevant forward guidance changes (revenue and adjusted EBITDA) plus margin improvements, which typically drive earnings-multiple and estimate revisions.
Market effects
Signals strength in eye-care franchises (dry-eye, contact lenses) and surgical premium mix, potentially supporting sentiment for ophthalmic peers.
U.S. pharmaceuticals and international growth details may influence regional estimate revisions for eye-care distributors and channel partners.
Dry-eye and glaucoma pipeline readouts (late Q3 and 2H 2026) can affect global ophthalmology sentiment and trial-risk pricing.
Counterpoint
Raised guidance could already be partially anticipated; investors may focus on execution risk for the dual-action dry-eye Phase 2 readout and upcoming Phase 3 start.
Key entities
- companyBausch + Lomb
Raised 2026 revenue and adjusted EBITDA guidance; discussed dry-eye and surgical pipeline milestones including ELIOS FDA submission and dual-action dry-eye Phase 2 readout timing.
